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Abstract
Blood levels of Glial Fibrillary Acidic protein (GFAP) reflect processes associated with differ-
ent types of CNS injury. Evidence suggests that GFAP is cleaved by caspases during CNS
injury, hence positioning GFAP fragments as potential biomarkers of injury-associated pro-
cesses. We set out to develop an assay detecting the neo-epitope generated by caspase-6
cleavage of GFAP (GFAP-C6), and to assess the ability of GFAP-C6 to reflect pathological
processes in patients suffering a cardiac arrest and subsequent global cerebral ischemia.
Anti-GFAP-C6 antibodies recognized their specific target sequence, and dilution and spike
recoveries in serum were within limits of ±20% reflecting high precision and accuracy of
measurements. Intra- and inter-assay CVs were below limits of 10% and 15%, respectively.
Serological levels of GFAP-C6 were significantly elevated 72 hours after CA (Mean±SD)
(20.39±10.59 ng/mL) compared to time of admission (17.79±10.77 ng/mL, p<0.0001), 24
hours (17.40±7.99 ng/mL, p<0.0001) and 48 hours (17.87±8.56 ng/mL, p<0.0001) after CA,
but were not related to neurological outcome at day 180. GFAP-C6 levels at admission, 24,
48, and 72 hours after cardiac arrest correlated with two proteolytic fragments of tau, tau-A
(r = 0.30, r = 0.40, r = 0.50, r = 0.53, p < 0.0001) and tau-C (r = 54, r = 0.48, r = 0.55, r = 0.54,
p < 0.0001), respectively. GFAP-C6 levels did not correlate with other markers of CNS dam-
age; total tau, NSE and S100B. In conclusion, we developed the first assay detecting a cas-
pase-6 cleaved fragment of GFAP in blood. Increased levels at 72 hours after cardiac arrest
as well as moderate correlations between GFAP-C6 and two other blood biomarkers of neu-
rodegeneration suggest the ability of GFAP-C6 to reflect pathological processes of the
injured brain. Investigations into the potential of GFAP-C6 in other types of CNS injury are
warranted.
PLOS ONE | https://doi.org/10.1371/journal.pone.0224633 November 6, 2019 1 / 19
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Jonesco DS, Hassager C, Frydland M,
Kjærgaard J, Karsdal M, Henriksen K (2019) A
caspase-6-cleaved fragment of Glial Fibrillary
Acidic Protein as a potential serological biomarker
of CNS injury after cardiac arrest. PLoS ONE 14
(11): e0224633. https://doi.org/10.1371/journal.
pone.0224633
Editor: Stephen D. Ginsberg, Nathan S Kline
Institute, UNITED STATES
Received: May 29, 2019
Accepted: October 17, 2019
Published: November 6, 2019
Copyright: © 2019 Jonesco et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The Danish research fund “Den Danske
Forskningsfond” supported this study by funding
DSJ PhD project. The TTM-trial was supported by
independent research grant from TrygFonden
(Denmark) (grant no: 7-12-0454). The work was
funded by the Swedish Heart-Lung Foundation and
the Swedish Research Council. DSJ, KH and MK
Introduction
Astrocytes are a predominant type of specialized glial cell in the CNS, providing metabolic and
trophic support of neurons and assisting in synaptic transmission[1]. Activation of astrocytes
is a prominent feature of traumatic brain injury (TBI), cerebral ischemia, as well as neurode-
generative diseases[1–3]. Concurrent upregulation of Glial Fibrillary Acidic Protein (GFAP),
which is the main constituent of intermediate filaments in astrocytes occurs[1]. As a conse-
quence, intensive focus has been put on GFAP and its unspecified breakdown products
(GFAP-BDPs) as possible markers of different types of injury to the CNS [4,5,14,15,6–13]. Sev-
eral studies have found GFAP levels to be elevated in CSF and blood of patients with mild to
severe Traumatic Brain Injury (TBI) and levels of GFAP reflect severity of injury [4–9]. Simi-
larly, publications on serological levels of GFAP after CA report increased levels after injury
[10,11] with the ability to separate good from poor neurological outcome 12 hours after CA
[12]. Also, CSF levels of GFAP are known to differentiate between patient with ischemic stroke
and healthy individuals within the first 24 hours after injury, and GFAP correlates to severity
of stroke [14,15]. Clearly, alterations in GFAP levels reflect processes associated with different
types of injury to the CNS. The degree of detail on processes underlying CNS injury, provided
by a biomarker, might increase by targeting disease-specific posttranslational modifications
(PTM) of proteins as biomarkers. Applying PTMs as markers of disease has proved beneficial
before. An example is seen in Alzheimer’s Disease (AD) where not only total tau but also phos-
phorylated tau and the γ-secretase-cleaved APP fragment, Aβ42, is applied in the diagnostic
and prognostic workup [16]. Likewise, in Alexander disease, a rare neurodegenerative disease
characterized by cytoplasmic proteinaceous aggregates containing GFAP, the proteolytic frag-
mentation of GFAP has been related to disease severity [17] and has been suggested to be cen-
tral in the pathogenesis [17,18]. Fragmentation of proteins by caspases is one possible process
resulting in PTMs [18–21]. Caspase-6 cleavage of GFAP is observed in vitro, resulting in a C-
terminal fragment unable to assemble into filaments as well as an N-terminal fragment prone
to aggregation [18]. Cleavage of GFAP by caspases is also observed in both apoptotic and non-
apoptotic astrocytes ex vivo [19–21]. In non-apoptotic astrocytes, caspases are believed to aid
in the rearrangement of the cytoskeleton as these cells become reactive [19,22]. Involvement of
caspases in cytoskeleton rearrangement is also evident within neurons [23–26]. In vitro and in
vivo investigations suggest that astrocytes undergo apoptosis during neurodegenerative dis-
ease, TBI and cerebral ischemia [20,27–31]. Furthermore, it is suggested that caspases are
involved in this process [20,28,29,32,33]. Pro-caspase-6 is observed in astrocytes after transient
focal cerebral ischemia in rats [32] and active caspase-6 localizes with GFAP in the brain of
patients with HIV-associated dementia [32,33]. We hypothesize that caspase-6-generated frag-
ments of GFAP (GFAP-C6) could reflect pathological processes underlying neurodegenera-
tion as a function of ischemia of the brain resulting from a cardiac arrest (CA). To test our
hypothesis, we set out to develop a highly specific and technically robust serum-based enzyme-
linked immunosorbent assays (ELISAs) for detection of the neo-epitope generated by caspase-
6 cleavage of GFAP, GFAP-C6. We then determined the levels of a GFAP-C6 in serum of CA
patients with global cerebral ischemia. Serum samples were obtained from a single-center, pro-
spective, observational sub-study comprising 171 patients enrolled at Copenhagen University
Hospital, Rigshospitalet in the TTM-Trial (November 2010 to July 2013) [34]. GFAP-C6 levels
in serum, collected at four time points following CA were assessed in relation to neurological
outcome after 180 days as well as other blood biomarkers, patient CA data and demographics.
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Material and methods
Reagents and peptides
All chemicals were purchased from Merck (Whitehouse Station, NJ, USA) and Sigma-Aldrich
(St. Louis, MO, USA). Monoclonal antibodies (mAb) were produced and validated using syn-
thetic peptides: a) Immunogenic peptide NLAQDLATVR-GGC-KLH (Keyhole-Limpet-
Hemocyanin), b) screening peptide NLAQDLATVR-biotin, c) selection peptide NLAQ-
DLATVR and d) elongated peptide DNLAQDLATVR, from Scilight Biotechnology LLC
(Beijing, China) as well as e) non-sense selection peptide AGRKRQSLQF and f) non-sense
screening peptide biotin-AGRKRQSLQF from Genscript (Nanjing, China).
Production of mAbs with high specificity for GFAP-C6
Anti-GFAP-C6 mAb was raised against the amino acid sequence 143NLAQDLATVR152 corre-
sponding to the N-terminal of the GFAP fragment generated by caspase-6 cleavage at Asn143.
The neo-epitope was blasted for homology to other proteins using the “NPS@: Network Pro-
tein Sequence Analysis with the UniprotKB/Swiss-prot database” software online [35]. Anti-
GFAP-C6 mAb was produced by s.c. immunization of 4-6-week-old Balb/C female mice with
200 μL emulsified antigen containing 50 μg immunogenic peptide. After consecutive immuni-
zations, the mouse displaying the highest antibody titer was boosted by injecting 50 μg immu-
nogenic peptide in 100 μl 0.9% NaCl solution intravenously. The spleen was isolated for cell
fusion and spleen cells were fused with SP2/0-Ag14 mouse myelomas, to produce immortal
antibody-producing hybridoma. The fusion cells were cultured in 96-well plates at 37˚C with
5% CO2. Monoclonal growth was ensured by standard limited dilution. Clones producing
mAb specifically recognizing the epitope sequence (NLAQDLATVR) but not an elongated
sequence (DNLAQDLATVR) were selected for sub-cloning. Last, monoclonal hybridoma
were expanded and antibodies purified from hybridoma supernatant using a prepacked
HiTrapTM Protein G Sepharose column (GE Healthcare Life Science, Buckinghamshire, UK).
Mice were housed under standardized conditions (20–23˚C, 30–60% relative humidity, and a
12-h/12-h light/dark cycle) and were caged five mice per cage in cage type lllH (1291H,
425x266x185mm, floor area 800cm2). They had access to food and water ad libitum, and the
general conditions were monitored daily by trained animal technicians. Red bumps after injec-
tion were expected. However, if a skin infection or tumor was found at the sites of injection,
the mouse would be terminated to reduce suffering and pain. Mice were sacrificed by cervical
dislocation. All the work on mice was approved by Beijing laboratory animal administration
office and animal ethics committee of Nordic Bioscience (Beijing).
Development of ELISAs specifically detecting GFAP-C6
A competitive ELISA was developed based on our mAbs, allowing specific detection of
GFAP-C6. Optimal buffers, incubation time and temperature as well as antibody and antigen
concentrations, were identified. The final settings for the ELISA were as follows: A 96-well
ELISA plate pre-coated with streptavidin (cat. no.11940279, Roche, Basel Switzerland) was fur-
ther coated with 2.5 ng/mL screening peptide dissolved in assay buffer (25 mM TBS-BTB, 2 g/
L NaCl, pH 7.4) for 30 min at 20˚C, 300 rpm. The plate was washed five times in wash buffer
(20 mM Tris, 0.1% Tween-20, 50 mM NaCl, pH 7.2). 20 μL/well of standard peptide or sample
was added followed by 100 μL/well of the anti-GFAP-C6 mAb diluted in assay buffer. The
plate was incubated for one h at 20˚C, 300 rpm before washing five times in wash buffer.
100 μL/well of horseradish peroxidase (HRP)-conjugated anti-mouse antibodies diluted in
assay buffer was added and the plate incubated for one hour at 20˚C, 300rpm. Again, the plate
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was washed five times. Then, 100 μL/well tetramethylbenzidine (TMB) (cat. no. 4380, Kem-
En-Tec, Taastrup, Denmark) was added and the plate incubated for 15 min at 20˚C, 300 rpm.
The colorimetric reaction was stopped by adding 100 μL/well of stopping solution (1%
H2SO4). The plate was measured at 450 nm with 650 nm as the reference (SpectraMax M;
Molecular Devices, CA, USA). A standard curve was produced by serial dilution of the selec-
tion peptide and plotted using a four-parameter curve fit model. Standard concentrations
were: 0.09, 0.37, 1.47, 5.86, 23.44, 93.75, 375.00, 1500.00 ng/mL. Data were analysed using the
SoftMax Pro v.6.3 software.
Technical validation. Specificity of the anti-GFAP-C6 mAbs in the context of the
GFAP-C6 ELISA was investigated. This was done by performing the established ELISA proce-
dure using a non-sense screening-peptide as well as serial dilutions of non-sense selection-
and elongated- peptide sequences. Linearity of dilution was determined by dilution of five
human serum samples and calculated as the recovery percentage of undiluted sample. Accu-
racy of the assay was assessed by the recovery percentage of spiking. Six human serum samples
of known GFAP-C6 concentration were spiked with six other human serum samples with
known GFAP-C6 concentrations. The recovery percentage was calculated as the actual con-
centration over the expected concentration of spiked samples. Inter- and intra-assay precision
was assessed by performing 10 independent analytical runs measuring duplicates of five differ-
ent serum samples and calculating the mean CV%. In order to assess possible interference in
the ELISA from endogenous analytes, high/low content of lipemia/lipids, (4.83/10.98 mM)
and biotin (3.00/9.00 ng/mL) as well as high content of hemoglobin (0.31mM) were added to
two different serum samples of known concentrations. Recovery percentage was calculated
with the normal serum samples as reference. Analyte stability was assessed by exposing serum
samples to repeated freeze/thaw cycles as well as different temperatures for various time inter-
vals. First, GFAP-C6 concentrations were determined in three different samples in four freeze/
thaw cycles and the recovery was calculated with the zero cycle as a reference. Second, three
samples were stored at either 4˚C or 20˚C for 0, 2, 4, 24, and 48 h before determining
GFAP-C6 concentrations and recovery was calculated with 0 h as a reference. The Lower
Limit of Detection (LLOD), Lower Limit of Quantification (LLOQ) and Upper Limit of Detec-
tion (ULOD) define the assay range within which quantification of serum is made with high
accuracy and precision. The LLOD was determined from 76 measurements of zero samples
(assay buffer) and calculated as the mean OD– 3 standard deviations. The OD value was then
interpolated into ng/mL based on the standard curve parameters. The lowest possible analyte
concentration that can be quantified with acceptable accuracy and precision is represented by
the LLOQ. To determine this value, three independent assay runs measuring quadruplicates of
two serial diluted serum samples were performed. A total impression score was calculated for
each dilution step taking three parameters into account: the analyte recovery as well as inter-
and intra-variations. The lowest possible concertation of analyte with an impression score
below 25% equals the LLOQ. The ULOD was established based on 10 independent determina-
tions of the highest standard peptide concentration and was calculated as mean–three standard
deviations.
Cleavage of human GFAP. In vitro cleavage of human GFAP with recombinant human
caspase-6 was performed. First GFAP was dissolved in dH2O at a concentration of 1 mg/mL
and caspase-6 was dissolved in PBS with 15% glycerol at a final concentration of 3.33 units/μL.
Protein and enzyme was mixed in cleavage buffer (50 mM HEPES, 50mM NaCl, 10 mM
EDTA, 10mM DTT, 0.1% (w/v) Chaps, 5% (v/v) Glycerol, pH: 7.2) in a ratio of 1.2:1 and incu-
bated at 37˚C for 24h. Cleavage was ended by placing the solutions at -80˚C. Solutions were
tested in the GFAP-C6 ELISA.
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Biological and clinical validation of GFAP-C6. GFAP-C6 was measured in serum sam-
ples from a prospective, observational sub-study comprising 171 patients enrolled at the
Copenhagen University Hospital, Rigshospitalet in the TTM-Trial (November 2010 to July
2013). The Ethics Committee of the Capital Region of Copenhagen approved the main study
protocol (H-1-2010-059). The primary goal of the TTM-trial was to investigate the benefit of
target temperature management. Details on trial design, statistical analysis plan and results
have been published [34,36,37]. Briefly, included in the study were comatose patients, 18 years
of age or older, admitted after out-of-hospital cardiac arrest of presumed cardiac cause. Exclu-
sion criteria were: Unwitnessed asystole as the primary rhythm, time between return of spon-
taneous circulation (ROSC) and screening > 4 hours, intracranial bleeding suspected or
confirmed, temperature on admission < 30˚C. Patients were randomly assigned to two tem-
perature regimes of 33˚C or 36˚C for 24 hours after CA. Patients were sedated, intubated and
mechanically ventilated. After 36 hours, sedation was lifted and the patients allowed to recover
spontaneously. Neurological outcome after 180 days was defined as good or poor based on
scores of the cerebral performance category (CPC) scale (CPC 1–2 = good; CPC = 3–5 = bad).
CPC 1, represents good cerebral performance or minor disability; 2, moderate disability; and
3, severe disability; 4, coma or vegetative state; and 5, death. Assessment of the CPC score was
performed blinded according to the TTM trial protocol [34]. Blood serum was collected 0, 24,
48 and 72 hours after ROSC and samples were aliquoted and placed at -80˚C for later analysis.
The primary end-point of this sub-study was neurological outcome at day 180. We did not dis-
tinguish between patients assigned to the two temperature regimes, as the target temperature
management at 33˚C was comparable to that of 36˚C [36].
Statistical analysis
Differences between groups were tested using the Student t-test or the Mann-Whitney U test.
Associations between variables were assessed using Spearman’s rho correlation coefficients.
The kinetics of GFAP-C6 were assessed using One-way ANOVA with repeated measures.
Adjustment for multiple comparisons was performed with Dunn’s multiple comparisons test.
Serum GFAP-C6 levels in patients with good versus bad outcome at different time points after
CA were compared using the Two-way ANOVA with repeated measures. Assumptions were
checked and met. Results are shown as Line plots with error bars or Scatter dot plots with the
mean or median and 95% CI indicated. The significant level was set at 0.05. Asterisks indicate
the following: �P< .05; ��P< 0.01; ���P< 0.001; ����P< 0.0001. Graphs and statistical analy-
ses were performed using GraphPad Prism version 7 (GraphPad Software, Inc., CA, USA)
Results
The GFAP-C6 ELISA is highly specific for the target sequence
To assess the specificity of the GFAP-C6 ELISA, we performed several investigations. First, we
blasted the neo-epitope sequence for homology to other proteins and found no homology with
other protein sequences than that of GFAP (S1 Fig). Subsequently we compared a dilution
series of selection peptide with that of elongated peptide, nonsense selection peptide and non-
sense screening peptide dilution series. Adding a single amino acid at the N-terminal of the
neo-epitope sequence disrupts the binding of anti-GFAP-C6 antibodies to a large extent. Like-
wise, dilution series of the non-sense selection peptide were not recognized by the antibodies,
while coating the plate with non-sense screening peptides resulted in complete lack of signal
(Fig 1). Lastly, in order to challenge the GFAP-C6 mAbs with fragments displaying a natural
tertiary structure resembling the endogenous GFAP-C6 to a larger extent than synthetic pep-
tides, we produced caspase-6-cleaved rhGFAP fragments in vitro and applied these in the
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GFAP-C6 ELISA. The assay only detected caspase-6 cleaved rhGFAP and not full-length
rhGFAP, caspase-6 or cleavage buffer (Fig 2). The results of these investigations demonstrate
high target specificity of the antibodies as applied in the GFAP-C6 ELISA.
The GFAP-C6 ELISA is technically robust with high accuracy and precision
The assay range, defined as the LLOQ and the ULOD, was determined to be 2.16ng/mL–
247.38ng/mL. The LLOD was determined to be 1.12ng/mL and the mean IC50 value was
8.41ng/mL. Diluting samples 1+1 to 1+5 allowed linearity of analyte dilution with recovery
percentages within 100±20% (Table 1). The ELISA showed high accuracy with a mean spiking
recovery of 106% using high analyte serum samples (Table 2). Recovery percentages of
GFAP-C6 levels in serum samples spiked with low and high levels of the common endogenous
serum analytes, biotin, lipid, and hemoglobin, show no interference from these analytes
(Table 3). Mean recovery percentages for low (3.00ng/mL) and high (9.00ng/mL) biotin are
102%. For low (4.83mM) and high (10.98mM) levels of lipid the mean recovery percentages
are 93% and 90%, respectively, and for high (0.31mM) levels of hemoglobin mean recovery
percentage is 93% (Table 3). Furthermore, stability of GFAP-C6 analyte was not affected by 1,
2, 3 or 4 freeze/thaw cycles as shown by recovery percentages of GFAP-C6 at 98%, 96%, 103%,
and 102%, respectively (Table 4). Further analysis of analyte stability was performed by placing
serum samples at 4˚C or 20˚C for 4, 24, and 48 hours before measuring GFAP-C6 concentra-
tions. Mean recovery percentages of GFAP-C6 levels in samples placed at 4˚C for 4, 24, and 48
hours were 97%, 99%, and 90%, respectively (Table 5). Mean recovery percentages of
GFAP-C6 levels in samples placed at 20˚C for 4, 24, and 48 hours were 88%, 80%, and 63%,
respectively (Table 5). Thus, stability of GFAP-C6 analyte is affected only if stored at 20˚C
between 24 and 48 hours. Inter- and intra-assay variation were determined to be 10% and 4%,
Fig 1. Peptide specificity test of monoclonal anti-GFAP-C6 antibodies. Shown are the binding of antibodies to
selection-, elongated-, non-sense selection- and non-sense coater peptides of concentrations within the measuring
range of each assay. An addition of a single amino acid (elongated peptide) disrupted the binding to a satisfying extent.
Non-sense peptides were completely imperceptible to the antibodies. Shown are the mean of two determinations
plotted with the standard deviation.
https://doi.org/10.1371/journal.pone.0224633.g001
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respectively, reflecting high technical stability of the GFAP-C6 ELISA (Table 6). An overview
of the technical parameters is given in Table 7.
Defining the TTM study and groups of good and unfavorable neurological
outcome
At the Copenhagen University Hospital, 171 patients with CA were included in the TTM
study. We had at least one serum sample available from 168 of these patients (98%). Levels of
GFAP-C6 did not differ between those patients who had, or had not, experienced CPR from
bystanders, had shockable or non-shockable initial rhythms or lactate levels above or below
the median value of the total cohort at admission (S2 Fig). Further, GFAP-C6 levels did not
correlate with time from CA to Return of Spontaneous Circulation (ROSC) at any of the blood
sampling time points (S1 Table). Patients with a good neurological outcome were significantly
younger (p = 0.0006), had a shorter time to ROSC (p = 0.001), lower lactate levels at time of
admission (p = 0.0027) and more often presented with a shockable rhythm (p< 0.0001) than
patients with an unfavorable neurological outcome (S2 Table). Generally similar to what others
have previously observed [38–42], these results are as expected.
Fig 2. Specificity test of GFAP-C6 ELISA. Shown are the signal obtained by GFAP-C6 ELISA in response to caspase-
6 cleaved rhGFAP, non-cleaved rhGFAP, caspase-6 and cleavage buffer incubated at 37˚C for 24 h. Concentrations
below LLOD were given the value of LLOD. Shown are the mean of two determinations plotted with the standard
deviation.
https://doi.org/10.1371/journal.pone.0224633.g002
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GFAP-C6 levels in serum are elevated 72 hours after Cardiac arrest but do
not correlate with neurological outcome
Levels of GFAP-C6 did not increase from time of admission to 24 hours or 48 hours after CA:
Mean (SD) 17.79 (10.77) ng/mL, 17.40 (7.99) ng/mL (p> 0.99) and 17.87 (8.56) ng/mL
(p = 0.35), respectively. On the other hand, a significant increase in GFAP-C6 levels was evi-
dent from time of admission as well as 24 hours and 48 hours after CA to 72 hours after CA:
Mean (SD) 20.39 (10.59) (p< 0.0001). This increase suggests that caspase-6 cleaved GFAP
may reflect processes related to CA and subsequent brain hypoxia (Fig 3). However, GFAP-C6
levels were not significantly different between patients of good versus unfavorable neurological
outcome within the first 72 hours of CA: Mean (SD) 18.04 (12.06) ng/mL versus 15.87 (7.05)
ng/mL, 17.59 (8.71) ng/mL versus 16.57 (5.99) ng/mL, 17.83 (9.30) ng/mL versus 17.44 (7.77)
Table 1. Dilution recovery of GFAP-C6 ELISA.
Dilution recovery of human serum analyte
Sample name Dilution GFAP-C6 (ng/mL) %RE from 1+0 %RE from 1+1 %RE from 1+2 %RE from 1+3
1 1+0 9.12
1+1 6.24 137
1+2 3.82 126 92
1+3 2.82 124 91 99
1+4 2.45 134 98 107 108
1+5
2 1+0 8.88
1+1 7.40 167
1+2 3.74 126 76
1+3 2.68 121 73 96
1+4 2.34 132 79 104 109
1+5 2.48 168 101 133 139
3 1+0 11.06
1+1 9.42 170
1+2 6.03 163 96
1+3 3.96 143 84 88
1+4 3.17 143 84 88 100
1+5
4 1+0 8.08
1+1 5.30 131
1+2 2.81 104 80
1+3
1+4 2.07 128 98 123
1+5 1.50 112 85 107
5 1+0 4.22
1+1 4.27 203
1+2 2.23 159 78
1+3 1.60 152 75 96
1+4 1.35 160 79 101 105
1+5 1.27 181 89 114 119
Mean 144 86 104 111
Going left to right, the columns contain information on: the extent of dilution, concentrations of GFAP-C6 in diluted serum samples, percent recovery of GFAP-C6 in
serum diluted from 1+0 to 1+3. RE indicates recovery.
https://doi.org/10.1371/journal.pone.0224633.t001
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ng/mL and 20.90 (11.85) ng/mL versus 19.77 (7.61) ng/mL at admission, 24, 48 and 72 hours
after CA, respectively (pinteraction = 0.36 and pgroup = 0.48) (Fig 4).
GFAP-C6 levels correlate with two other proteolytic fragments, tau-A and
tau-C
GFAP-C6 did not correlate to validated fluid biomarkers of brain injury such as neuron-spe-
cific enolase (NSE), S100B or total tau (T-tau) at any time point (S3 Table). Correlations to
NSE were (r = 0.14; p = 0.09) 24 hours after CA, (r = 0.13; p = 0.13) 48 hours after CA and
(r = 0.12; p = 0.21) 72 hours after CA. Correlations to S100B were (r = 0.07; p = 0.45) 24 hours
after CA, (r = 0.05; p = 0.55) 48 hours after CA and (r = 0.02; p = 0.85) 72 hours after CA.
Table 2. Spiking recovery of in GFAP-C6 ELISA.
Spiking recovery of human serum analyte
Sample name Serum (ng/mL) Spike (ng/mL) Expected spiked serum (ng/mL) Measured spiked serum (ng/mL) %RE %Mean RE
2 4.63 6.99 11.63 12.69 109 96
3 3.49 5.48 8.96 8.55 95
4 4.89 6.80 11.69 10.73 92
5 4.38 3.51 7.89 6.56 83
6 2.94 5.54 8.48 7.63 90
7 1.71 3.44 5.15 5.58 108
2 4.63 2.83 7.46 9.78 131 110
3 3.49 2.80 6.29 6.25 99
4 4.89 3.66 8.55 8.38 98
5 4.38 1.48 5.86 5.84 100
6 2.94 2.55 5.49 5.84 106
7 1.71 1.53 3.25 4.16 128
3 3.49 1.33 4.82 5.40 112 112
Mean 106
Going left to right, the columns contain information on: measured concentrations of GFAP-C6 in serum samples, measured concentration of GFAP-C6 in serum
samples for spiking, expected concentration of spiked serum samples, measured concentration of spiked serum samples, percent recovery of GFAP-C6 analyte and
mean percent recovery in all samples. RE indicate recovery.
https://doi.org/10.1371/journal.pone.0224633.t002
Table 3. Interference of endogenous analytes in GFAP-C6 ELISA.
Interference of endogenous analytes
Hemoglobin Biotin Lipid
Ctrl High Ctrl High Low Ctrl High Low
Serum sample 1
GFAP-C6 ng/mL 8.12 7.66 8.20 8.89 8.41 8.75 8.54 7.95
%RE of Ctrl 100 94 100 108 103 100 98 91
Serum sample 2
GFAP-C6 ng/mL 5.03 4.58 4.80 4.60 4.83 5.25 4.66 4.66
%RE of Ctrl 100 91 100 96 101 100 89 89
Mean %RE 93 102 102 93 90
Going left to right, the columns contain information on measured concentrations of GFAP-C6 in serum samples spiked with: Ctrl or high levels of hemoglobin, Ctrl,
high or low levels of Biotin and Ctrl, high or low levels of Lipid. Going from top to bottom, rows contain information on serum sample ID, GFAP-C6 concentration in
serum spiked with hemoglobin, biotin, lipid analytes and lastly % recovery from the Ctrl sample. Ctrl indicate control; RE, recovery.
https://doi.org/10.1371/journal.pone.0224633.t003
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Correlations to T-tau were (r = -0.04; p = 0.65) 24 hours after CA, (r = 0.05; p = 0.59) 48 hours
after CA and (r = 0.00; p = 0.96) 72 hours after CA. Interestingly, modest correlations were
observed between levels of GFAP-C6 and two proteolytic fragments of tau, tau-A and tau-C,
but not total tau, at all time points (Fig 5 and S3 Table) possibly suggesting that proteolytic
fragmentation reflects pathological processes not reflected by total protein levels. Correlations
tau-A were (r = 0.30; p< 0.0001) at admission, (r = 0.40; p =< 0.0001) 24 hours after CA,
(r = 0.50; p =< 0.0001) 48 hours after CA and (r = 0.53; p = < 0.0001) 72 hours after CA. Cor-
relations to tau-C were (r = 0.54; p =< 0.0001) at admission, (r = 0.48; p =< 0.0001) 24 hours
after CA, (r = 0.55; p = < 0.0001) 48 hours after CA and (r = 0.54; p =< 0.0001) 72 hours after
CA. Further, GFAP-C6 levels at admission correlated with levels of C-reactive protein
(r = 0.23; p = 0.0030) suggesting that the processes leading to caspase-6 mediated fragmenta-
tion of GFAP are to some extent connected with processes of the early immunologic response
to CA (S3 Table).
Discussion
In this study, we have presented a novel, competitive ELISA targeting caspase-6-cleaved GFAP
in serum and evaluate the biological relevance of this neo-epitope in 168 CA patients with
global cerebral ischemia. This is the first study specifically measuring the caspase-6 cleaved
fragment of GFAP in serum. We showed that the GFAP-C6 ELISA provides reliable
Table 4. Stability of GFAP-C6 during repeated freeze/thaw cycles.
Analyte stability–Freeze/Thaw
GFAP-C6 (ng/mL)
Sample name 0 cycle 1 cycle %RE 2 cycle %RE 3 cycle %RE 4 cycle %RE
1 6.52 6.14 94 6.83 105 7.08 109 7.06 108
2 3.84 4.04 105 3.59 93 4.05 105 4.02 104
3 9.58 9.12 95 8.58 90 9.03 94 8.96 94
Mean %ER 98 96 103 102
Going left to right, the columns contain information on measured concentrations of GFAP-C6 in serum samples exposed to freeze/thaw cycles: 0, 1, 2, 3 and 4 times.
The %recovery from the 0 cycle sample after repeated freeze/thaw cycles is depicted adjecent to each freeze/thaw cycle. RE indicates recovery.
https://doi.org/10.1371/journal.pone.0224633.t004
Table 5. Stability of GFAP-C6 as a function of time and temperature.
Analyte stability–temperature
Sample name GFAP-C6 (ng/mL)
4˚C T: 0 hours T: 4 hours %RE from T: 0 T: 24 hours %RE from T: 0 T: 48 hours %RE from T: 0
1 5.39 4.82 89 5.23 97 4.56 85
2 8.80 8.21 93 8.27 94 7.67 87
3 10.58 11.61 110 11.10 105 10.48 99
Mean %ER 97 99 90
20˚C
1 5.39 4.51 84 4.47 83 2.56 47
2 8.80 7.86 89 6.70 76 6.01 68
3 10.58 9.76 92 8.57 81 7.87 74
Mean %ER 88 80 63
Going left to right, the columns contain information on measured concentrations of GFAP-C6 in serum samples placed at either 4˚C or 20˚C for: 0, 4, 24 and 48 hours.
The %recovery from the 0 hour sample after increased time exposure to either 4˚C og 20˚C is depicted adjecent to each time slot. RE indicates recovery. T, time
https://doi.org/10.1371/journal.pone.0224633.t005
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measurements and we observe increased levels of GFAP-C6 in serum from CA patients which
suggests a possible relation of this biomarker to processes affected by CNS injury.
The GFAP-C6 ELISA measures serum levels of GFAP-C6 with high
precision and accuracy
To build the assay, we raised highly specific mAbs specifically recognizing the neo-epitope on
GFAP fragments resulting from a cleavage at Asn143 by caspase-6. The ELISA was highly spe-
cific for its target, as shown using both synthetic peptides as well as caspase-6 cleaved rhGFAP.
Performing spiking- and dilution recoveries, we found that a sample dilution of 1+1 provided
both high precision and accuracy of measurements and allowed most samples to be within the
measurement range of the assay. Additional investigations on precision and accuracy of the
assay were performed using endogenous serum analytes, hemoglobin, lipid, and biotin, which
may interfere with the binding of epitopes by antibodies or mimic the action of HRP causing
falsely high or falsely low results [43–45]. We did not see any interference from these analytes
Table 6. Inter- and Intra-assay variability of the GFAP-C6 ELISA.
Inter- and Intra-assay variability
Sample name GFAP-C6 (mean ng/mL) Intra-assay variability% Inter-assay variability%
Ctrl1 16.57 3.11 9.28
Ctrl2 7.31 4.97 8.91
QC1 8.21 3.56 10.23
QC2 10.25 2.70 7.20
QC3 5.88 3.61 11.80
QC4 4.10 8.49 15.92
QC5 16.29 2.86 7.71
Mean 4.19 10.15
Going left to right, the columns contain information on: mean concentrations of either selection peptide in buffer (Ctrl1 and Ctrl2) or GFAP-C6 in serum samples
(QC1-5), Intra-assay variability and Inter-assay variability based on ten analytical runs.
https://doi.org/10.1371/journal.pone.0224633.t006
Table 7. Technical specifications of the GFAP-C6 ELISA.
GFAP-C6 assay Technical parameters
Detection range (LLOQ—ULOD) 2.16–247.38 ng/mL
Lower limit of detection (LLOD) 1.12 ng/mL
IC50 8.41 ng/mL
Intra-assay variation 5%
Inter-assay variation 11%
Dilution recovery 100±20%
Spiking recovery 100±20%
Recovery in Biotin low, high 102%, 102%
Recovery in Lipid low, high 93%, 90%
Recovery in Hemoglobin low, high -, 93%
Analyte Stability, 4˚C 4, 8, 48h 97%, 99%, 90%
Analyte Stability, 20˚C 4, 8, 48h 88%, 80%, 63%
Freeze/Thaw, 1, 2, 3, 4 times 98%, 96%, 103%, 102%
Listed are the technical parameters of the GFAP-C6 ELISA. LLOQ indicates lower limit of quantification; ULOD,
upper limit of detection; LLOD, lower limit of detection.
https://doi.org/10.1371/journal.pone.0224633.t007
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suggesting that our measurements of GFAP-C6 are reliable across serum samples with differ-
ent compositions of hemoglobin, lipids, and biotin. Furthermore, we assessed the implications
of repeated freeze/thaw cycles of serum samples as well as exposure to different temperatures
for various time intervals on biomarker levels as these factors are relevant in practice and may
affect analyte stability [46–48]. We found no indication of alterations to the measured bio-
marker levels as a consequence of repeated freeze/thaw cycles or storage of serum at 4˚C for
up to 48 hours. On the other hand, serum samples placed at 20˚C for 48 hours showed a mean
decrease of GFAP-C6 levels of 37%. Taken together, these data suggest that for the GFAP-C6
ELISA, normal handling of serum samples does not pose a problem for reliable measurements
of biomarker levels as long as care is taken not to expose the samples to room temperature for
an excessive amount of time. Finally, the GFAP-C6 assay showed high technical reliability
Fig 3. Serological levels of GFAP-C6 in CA patients at admission, 24, 48, and 72 hours after CA. Depicted in a
scatter dot plot are levels of GFAP-C6 measured in the GFAP-C6 ELISA in serum of CA patients at admission, 24, 48,
and 72 hours after CA. Error bars signify the mean with 95% confidence intervals. Significance of differences in
biomarker levels is determined using One-way ANOVA with repeated measures. Adjustment for multiple
comparisons was performed with Dunn’s multiple comparisons test. ���� indicates a P value below 0.0001.
https://doi.org/10.1371/journal.pone.0224633.g003
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with inter- and intra assay variations well within limits of 15% and 10%, respectively. Alto-
gether, we have produced a technically robust ELISA capable of quantifying the GFAP-C6
level in serum with high specificity, precision, and accuracy.
Serum levels of GFAP-C6 increase 72 hours after CA, but do not predict
neurological outcome
We see a significant increase in GFAP-C6 at 72 hours after CA suggesting that global cerebral
ischemia affects processes related to the cleavage of GFAP by caspase-6. The literature on
Fig 4. Serological levels of GFAP-C6 in CA patients of Good or Unfavorable neurological outcome at admission,
24, 48, and 72 hours after CA. Levels of GFAP-C6 measured in the GFAP-C6 ELISA in serum of CA patients of good
or unfavorable neurological outcome at admission, 24, 48, and 72 hours after CA, are depicted as Line plots with error
bars signifying the 95% confidence interval. Significance of differences in biomarker levels is determined using the
Two-way ANOVA with repeated measures.
https://doi.org/10.1371/journal.pone.0224633.g004
Fig 5. Correlations between GFAP-C6 levels and tau-A and tau-C levels at time of admission, 24, 48, and 72 hours after
CA. Levels of GFAP-C6 measured in the GFAP-C6 ELISA in serum of CA patients are correlated to serological levels of the
proteolytic fragments of tau, tau-A and tau-C at admission, 24, 48, and 72 hours after CA. Listed are the Spearman’s rho
correlation coefficients, r, with the 95% confidence interval. P values represent the significance of correlation.
https://doi.org/10.1371/journal.pone.0224633.g005
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serological levels of GFAP is scarce. However, the few publications on the subject suggest that
GFAP levels increase 24–48 hours after CA, showing differential levels between outcome
groups at 12 hours after injury [10–12]. This is in line with a hypothetical model on the tempo-
ral profile of brain injury markers following CA, categorizing GFAP as a ‘sustained acute
marker’ which increases in levels around 12 hours after CA, peaks at 24 hours and reaches pre-
CA levels between 48–96 hours [49].
To our knowledge, this is the first investigation specifically targeting the caspase-6 cleaved
GFAP fragment as a marker of brain injury. Based on previous observations on serological lev-
els of full-length GFAP following CA, the increase of GFAP-C6 appears later. However, GFAP
measurements in different CA cohorts can not be directly compared and future investigations
into the temporal relation between full-length GFAP and GFAP-C6 would be of interest.
There are several possible explanations as to why the caspase-cleaved GFAP fragment may
show another temporal profile than its full-length counterpart. One possibility is that transport
across the blood-brain-barrier differs between GFAP-C6 and full-length GFAP. This has been
suggested to explain the lack of correlation between T-tau and two fragments of tau measured
in serum obtained from the same CA cohort as applied in this study [50]. Another possibility
is, that the cleavage of GFAP-C6 is a limiting factor in relation to how fast the fragment is gen-
erated. Only a few studies have investigated the effect of cerebral ischemia on the expression
and activation of caspase-6 specifically. Following focal ischemic injury in rats, procaspase-6
shows moderate immunostaining in neurons and astrocytes within the stroke penumbra 12
hours after injury [32] and activation 24 hours after injury [51]. In a canine model of CA, how-
ever, activated caspase-6 appeared in brain homogenates as early as 10 minutes following
reperfusion [52]. Thus, based on the few data available on the temporal profile of caspase-6 fol-
lowing ischemic brain injury, it does not appear that the cleavage of GFAP will limit the forma-
tion and subsequent release of GFAP-C6 compared to that observed for full-length GFAP.
Within the available timeframe of this study, GFAP-C6 serum levels are not indicative of
neurological outcome at day 180 after CA. However, as the increase in GFAP-C6 serum levels
is only initiating at 72 hours after injury, it is possible that GFAP-C6 levels are indeed reflect-
ing pathological processes in the injured CNS and thus, levels at later time points may be indic-
ative of neurological outcome. In the setting of CA, a possible prognostic value of GFAP-C6
levels later than 72 hours after CA is irrelevant as levels of the currently most used biochemical
marker of prognosis, NSE, shows prognostic ability at 24 hours after CA [53,54]. However, in
a setting of slowly evolving CNS damage, such as the pathology underlying dementias,
GFAP-C6 serum levels might show diagnostic and/or prognostic abilities by reflecting pro-
cesses affected by CNS injury, as suggested in this study. In support of this, several studies on
CSF- and blood levels of total GFAP in patients of different dementia types, suggest that pro-
cesses underlying neurodegenerative diseases affect the level of GFAP [55–60]. Also, caspase-6
activity has been associated with pathological processes underlying AD and is emerging as an
early event that, if inhibited, may prevent progression of AD [61]. Thus, it is conceivable that
caspase-6 cleavage of GFAP might add valuable information for the diagnosis and/or progno-
sis of dementia.
GFAP-C6 correlates with two other brain protein fragments, tau-A and
tau-C, but not total tau
GFAP-C6 did not correlate to validated fluid biomarkers of brain injury such as NSE, S100B
or T-tau at any time point. However, levels of two proteolytic fragments of tau, tau-A and tau-
C, previously shown to be associated with AD as well as severity of sports-related head trauma
[62–65], showed a modest correlation with levels of GFAP-C6 at all time points. The lack of
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correlation between GFAP-C6 and markers of injury, T-tau and NSE, is surprising. However,
levels of the two other proteolytic fragments, tau-A and tau-C, did not correlate with T-tau or
NSE, either [50]. In light of these findings, future studies on the correlation between GFAP-C6
and its full-length counterpart, GFAP, could provide interesting knowledge on the biology
behind GFAP-C6 formation and release. The lack of correlation between fragments GFAP-C6,
tau-A, tau-C and full-length proteins, tau and NSE, might suggest that proteolytic fragmenta-
tion of proteins, as a consequence of CNS injury, reflects different processes than total level of
protein. As tau-A and tau-C fragments have shown utility within diagnosis of AD and reflect
severity of AD as well as severity of TBI, their modest correlation to GFAP-C6 provides some
indication that GFAP-C6 might also provide information on pathological processes of the
injured brain.
In conclusion, we developed a robust ELISA assay capable of quantifying serum levels of
the caspase-6 cleaved fragment of GFAP, GFAP-C6, with high precision, and accuracy. We
have shown that levels of this proteolytic fragment start to increase at 72 hours after CA and
data of this study suggest a possible ability of GFAP-C6 to reflect pathological processes of the
injured brain. Based on this preliminary investigation on the potential of GFAP-C6 as a sero-
logical marker of CNS injury, it would be of interest to investigate the biology behind forma-
tion and release of GFAP-C6 as well as its potential as a marker of other types of CNS injuries.
Supporting information
S1 Fig. Significant alignments of the neo-epitope sequence of GFAP-C6. Shown are the two
sequences producing significant alignments to the neo-epitope sequence of GFAP-C6. The
sequence was blasted for homology to other proteins using the “NPS@: Network Protein
Sequence Analysis with the UniprotKB/Swiss-prot database” software online.
(TIF)
S2 Fig. Association of CA characteristics with GFAP-C6 levels at admission, day 2, 3 and 4.
Levels of GFAP-C6 measured in the GFAP-C6 ELISA in serum of CA patients at admission,
day 2, 3 and 4, are depicted as dot plots with error bars signifying the 95% confidence interval.
Compared at each time point is GFAP-C6 levels in those patients who had, or had not, experi-
enced CPR from bystanders, had shockable or non-shockable initial rhythms and lactate levels
above or below the median value of the total cohort at admission. Significance of differences in
biomarker levels is determined using the Mann Whitney U test.
(TIF)
S1 Table. Correlation between GFAP-C6 and Time from CA to ROSC. Listed are the Spear-
man’s rho correlation coefficients, r, with the 95% confidence interval. P values represents the
significance of correlation.
(DOCX)
S2 Table. Cardiac arrest data in groups of neurological outcome. Data are presented as
mean±SD or median and lower to upper quartile (IQR) as appropriate. P value represents
comparison between groups of good and unfavorable neurological outcome. CPR indicates
cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; min, minutes; mM,
millimolar; n, number of patients.
(DOCX)
S3 Table. Correlation between GFAP-C6 and other blood biomarkers. Listed are the Spear-
man’s rho correlation coefficients, r, with the 95% confidence interval. P values represents the
significance of correlation. CA indicates cardiac arrest; tau-A, ADAM10 cleaved tau fragment;
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tau-C, caspase-3 cleaved tau fragment; HGB, hemoglobin; CRP, C-reactive protein; NSE, Neu-
ron specific enolase; S100B, S100 calcium-binding protein B; T-tau, total tau; n, number of
patients.
(DOCX)
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